Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 7429.102 | 1.0033 | 1.0027 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 7429.102 | 1.0045 | 1.0037 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 7429.102 | 1.0439 | 1.0356 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 7429.102 | 0.9914 | 0.9930 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 7429.102 | 1.0095 | 1.0078 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 7429.102 | 1.0083 | 1.0068 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 0.288 | uM | 7429.102 | 0.9687 | 0.9740 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 1.44 | uM | 7429.102 | 0.9502 | 0.9584 | 2.4347 | |
| HBL-100 | Unknown | Unknown | Trastuzumab | HER2 | ErbB | 7.2 | uM | 7429.102 | 0.9103 | 0.9243 | 2.4347 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9233.124 | 1.0299 | 1.0598 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9233.124 | 0.9880 | 0.9760 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9233.124 | 1.0703 | 1.1408 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9233.124 | 0.9937 | 0.9873 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9233.124 | 1.0557 | 1.1116 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9233.124 | 0.9925 | 0.9850 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9233.124 | 0.7387 | 0.4770 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9233.124 | 1.0429 | 1.0858 | 0.9990 | |
| HCC1143 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9233.124 | 0.9061 | 0.8121 | 0.9990 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9254.124 | 0.9951 | 0.9878 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9254.124 | 1.1860 | 1.4711 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9254.124 | 1.1088 | 1.2731 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9254.124 | 1.0656 | 1.1640 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9254.124 | 1.0305 | 1.0759 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9254.124 | 1.1972 | 1.4998 | 0.8067 | |
| HCC1395 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9254.124 | 1.0736 | 1.1842 | 0.8067 |